

Re Amended
12/A
12-18-01
DT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Asghar, et al
Serial No. : 09/381,055 (U.S. National Stage
of International Application No. PCT/SE99/00702)
Examiner : To Be Assigned
Filed : September 13, 1999 Group Art Unit: To Be Assigned
For : NOVEL USE

5/10

I hereby certify that this paper is being
deposited with the United States Postal
Service as first class mail in an envelope
addressed to : The Assistant Commissioner
for Patents, Washington, D.C. 20231, on
October 27, 2000.

Richard J. Sterner
Agent Name

Richard J. Sterner
Signature

35,372
PTO Reg. No.

October 27, 2000
Date of Signature

RECEIVED

19 DEC 2000

Legal Staff

BOX PCT

The Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Preliminary to examination on the merits, please amend the
application as follows:

In the claims:

1. (amended) Use a compound having NMDA receptor antagonist
activity in the manufacture of a medicament for the treatment of
irritable bowel syndrome (IBS).
2. (amended) Use according to claim 1 wherein the compound
having NMDA receptor antagonist activity is a non-competitive
NMDA receptor antagonist.